Logo image
Back
Tumor microenvironment-responsive nanogel for therapeutic delivery of interleukin-12
Thesis   Open access

Tumor microenvironment-responsive nanogel for therapeutic delivery of interleukin-12

Dimitrios C. Arhontoulis
Master of Science (M.S.), Drexel University
Jun 2016
DOI:
https://doi.org/10.17918/etd-6834
pdf
Arhontoulis_Dimitrios_20163.48 MBDownloadView
PDF Open Access Open Access (License Unspecified)

Abstract

Cancer--Immunotherapy Biomedical Engineering Interleukins
Various forms of immunotherapy have arisen and shown promise in treating cancer. The administration of cytokines such as Interleukin-12 (IL-12) was thought to robustly stimulate innate immunity, and increase the number of endogenous tumor specific cytotoxic T-cells. However, patients enrolled in clinical trials involving the administration of IL-12 were reported to have IFN[gamma] toxicity, and suffered from multiple organ system complications and in some instances, death. To address this issue, a tumor microenvironment-responsive nanogel composed of modified hyaluronic acid has been developed. This hypoxia sensitive methacrylated hyaluronic acid (HS- MAHA) aims to actively release IL-12 in the presence of the hypoxic tumor microenvironment, and eliminate the systemic toxicity exhibited in the intravenous administration of recombinant human IL-12. The nanogel has also shown increased degradation in the presence of hyaluronidase, indicating an additional component of tumor microenvironmentsensitivity. The nanogel is able to differentiate CD4+ T-cells into the Th1 Phenotype in vitro, and recruit an increased number of tumor specific cytotoxic T-cells in vivo. The particles have shown sufficient accumulation in the tumor, while avoiding accumulation in the brain, heart, and lungs. Furthermore, the administration of antiPD1 antibody in combination with the nanogel containing IL-12 has shown delayed tumor growth in an aggressive B16-F10 melanoma model.

Metrics

37 File views/ downloads
25 Record Views

Details

Logo image